Clinical Trials Arena January 14, 2026
Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and acquisitions.
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few years. Key priorities outlined by Graham include maximising the on-market portfolio to sustain growth until 2028, delivering key launches to support momentum, and preparing wide entry into novel disease areas (Alzheimer’s, obesity) via new molecular entities (NMEs) with a broad and diversified pipeline.
The company is on track to achieve its 2025 financial goal, with YTD sales by September 2025 reaching CHF 35.6bn ($44.5 bn), CHF 18bn ($22.5bn) coming from its oncology and haematology portfolio. The currently marketed portfolio continues...
Today's Sponsors
Today's Sponsor